publication date: Oct. 5, 2018

Craig Thompson resigns from two corporate boards as MSK crisis shifts to board roles

By Paul Goldberg

Craig Thompson, president and CEO of Memorial Sloan Kettering Cancer Center, resigned from two corporate boards of directors—the pharmaceutical company Merck & Co., and Charles River Laboratories International Inc., a company focused on early-stage drug development and manufacturing of novel compounds.

Thompson announced his resignation from the corporate boards in an email to the MSK faculty and staff Oct. 2.

“I’ve heard from a number of you that you’d like me to be even more present at MSK,” Thompson wrote. “I take that feedback seriously and intend to lead by example. To that end, I am resigning from my positions as a member of the Board of Directors of Merck and Charles River, effective immediately. I believe this is the right decision for Memorial Sloan Kettering and will allow me to redouble my focus on MSK priorities: quality patient care, faculty, scientists, and staff.”

The scandal began on Sept. 8, when The New York Times and ProPublica published a story stating that José Baselga, MSK’s chief medical officer and physician-in-chief at the time, had systematically failed to disclose conflicts of interest. On Sept. 16, the Times published an editorial about conflicts of interest at the cancer … Continue reading Craig Thompson resigns from two corporate boards as MSK crisis shifts to board roles

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.